Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.039 AUD | -4.88% | -18.75% | +77.27% |
May. 01 | Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6% | MT |
Apr. 09 | Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.36M 2.22M |
---|---|---|---|---|---|
Net income 2022 | -2M -1.32M | Net income 2023 | -2M -1.32M | EV / Sales 2022 | - |
Net cash position 2022 | 1.1M 731K | Net cash position 2023 | 401K 265K | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.54
x | P/E ratio 2023 |
-1.35
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 63.89% |
1 day | -4.88% | ||
1 week | -18.75% | ||
Current month | -18.75% | ||
1 month | -4.88% | ||
3 months | +62.50% | ||
6 months | +34.48% | ||
Current year | +77.27% |
Managers | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Simon Erskine
PRN | Corporate Officer/Principal | - | 21-12-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Brookes
CEO | Chief Executive Officer | 63 | 19-01-22 |
John Michailidis
COO | Chief Operating Officer | - | - |
Nicholas Haslam
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 0.039 | -4.88% | 31,000 |
24-05-10 | 0.041 | -4.65% | 40,000 |
24-05-09 | 0.043 | +19.44% | 93,453 |
24-05-08 | 0.036 | -21.74% | 201,969 |
24-05-07 | 0.046 | -4.17% | 34,734 |
Delayed Quote Australian S.E., May 13, 2024 at 01:14 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+77.27% | 4.33M | |
+29.98% | 682B | |
+30.86% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.70% | 240B | |
+9.76% | 209B | |
-8.55% | 203B | |
+7.09% | 165B |
- Stock Market
- Equities
- ANR Stock